Reiki therapy to help patients with gynecological cancers undergoing brachytherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of Reiki therapy in alleviating symptoms for patients receiving their first brachytherapy treatment for gynecological malignancies. Participants will be randomly assigned to either receive Reiki therapy or standard care during the waiting period before their treatment. The study will measure various outcomes, including anxiety, pain, and depression, through questionnaires administered on the treatment day and at a three-month follow-up. The goal is to determine if Reiki therapy can provide significant benefits compared to usual care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject aged ≥ 18 years.
* Pathologically confirmed malignancy of the endometrium, cervix, vagina or vulva.
* Eligible to undergo brachytherapy treatment as an outpatient procedure.
* Able to read and understand English and/or Spanish.
* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
* Willing to participate in either the Reiki therapy or standard of care arm regardless of treatment assignment.

Exclusion Criteria:

* Prior brachytherapy treatment for a gynecological malignancy.
* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.

Where it's running

• Huntsman Cancer Institute
  Salt Lake City, Utah, United States Recruiting

Study contacts

• Principal investigator: Lindsay Burt, MD — Huntsman Cancer Institute
• Study coordinator: David Samuel
• Email: David.Samuel@hci.utah.edu
• Phone: 801-587-4713

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Using Belzutifan to treat recurrent clear cell ovarian carcinoma

  This study is testing if a new targeted therapy called Belzutifan can help people with recurrent clear cell ovarian cancer feel better and manage their disease.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06677190

• Examining the effects of brachytherapy on gynecological cancers

  This study looks at how well brachytherapy works for women aged 18 to 80 with different types of gynecological cancers.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT05242861

• Collecting specimens and data for early detection and prevention of ovarian cancer

  This study is trying to find better ways to detect and prevent ovarian cancer early by collecting blood and tissue samples from people at high risk.

  Recruiting Northwestern University · Chicago, Illinois · NCT00005095

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.